



TARGETED LUNG DENERVATION BIBLIOGRAPHY

1. Shah PL, Slebos DJ, Sue R, Bhatt SP, Ghattas C, Strange C, Degano B, Valipour A, Eisenmann S, De Cardenas J, Marquette CH, Soto-Soto J, Sciurba FC, Conway F, Tonkin J, Tana A, Marchetti N, Hartman JE, Heluain V, Guibert N, Criner GJ; **AIRFLOW-3 Study Group. Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3).** *Am J Respir Crit Care Med* 2025 www.atsjournals.org/doi/abs/10.1164/rccm.202502-0404OC.
2. Hartman JE, Herth FJF, Shah P, Pison C, Valipour A, Slebos DJ, Group A-S. **Computed tomographic airway morphology after targeted lung denervation treatment in COPD.** *Respir Med* 2023; 206: 107059.
3. Srikanthan K, Kistemaker L, Slebos DJ, Gesierich W, Darwiche K, Bonta P, Deslee G, Shah P, Gosens R. **Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD.** *ERJ Open Res* 2022; 8.
4. Conway F, Tonkin J, Valipour A, Pison C, Schumann C, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Skowasch D, Johnson PJ, Slebos DJ, Shah PL, Group A-TS. **Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.** *Respiration; international review of thoracic diseases* 2022; 101: 1069-1074.
5. Hartman JE, Conway F, Degano B, Augustijn SWS, Herth FJF, Mayr A, Chacaroun S, Tonkin J, Valipour A, Slebos DJ. **Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD.** *Respir Med* 2021; 188: 106604.
6. Hartman JE, Srikanthan K, Caneja C, Ten Hacken NHT, Kerstjens HAM, Shah PL, Slebos DJ. **Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings.** *Respiration; international review of thoracic diseases* 2022; 101: 184-189.
7. Pison C, Shah PL, Slebos DJ, Ninane V, Janssens W, Perez T, Kessler R, Deslee G, Garner JL, Hartman JE, Degano B, Mayr A, Mayse M, Peterson AD, Valipour A. Correction to: **Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.** *Respir Res* 2021; 22: 83.
8. Valipour A SP, Herth FJ, Pison C, Schumann C, Hübner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Perez T, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Conway F, Duller M, Mayse M, Norman HS, Slebos DJ. **Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.** *International Journal of Chronic Obstructive Pulmonary Disease* 2020; 15: 2807-2816.
9. Mayse ML, Norman HS, Peterson AD, Rouw KT, Johnson PJ. **Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures.** *Respir Res* 2020; 21: 117.



10. Slebos DJ, Degano B, Valipour A, Shah PL, Deslee G, Sciurba FC, Group A-TS. **Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaïra(R) lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).** *BMC Pulm Med* 2020; 20: 41.
11. Valipour A, Mayse ML, Peterson AD, Johnson PJ, Rouw KT, Asadi S, Hummel JP. **Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans.** *Respiration; international review of thoracic diseases* 2019: 1-6.
12. Slebos DJ, Shah PL, Herth FJ, Pison C, Schumann C, Hubner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Perez T, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Srikanthan K, Duller M, Valipour A, Group A-TS. **Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe COPD (AIRFLOW): A Multicenter Randomized Controlled Trial.** *American journal of respiratory and critical care medicine* 2019.
13. Valipour A, Shah PL, Pison C, Ninane V, Janssens W, Perez T, Kessler R, Deslee G, Garner J, Abele C, Hartman JE, Slebos DJ, On behalf of the A-SG. **Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.** *Respiration; international review of thoracic diseases* 2019: 1-11.
14. Hummel JP, Mayse ML, Dimmer S, Johnson PJ. **Physiologic and histopathologic effects of targeted lung denervation in an animal model.** *Journal of applied physiology* 2019; 126: 67-76.
15. Valipour A, Asadi S, Pison C, Jondot M, Kessler R, Benneddif K, Deslee G, Verdier M, Slebos DJ, Mayse M. **Long-term safety of bilateral targeted lung denervation in patients with COPD.** *International journal of chronic obstructive pulmonary disease* 2018; 13: 2163-2172.
16. Koegelenberg CF, Theron J, Slebos DJ, Klooster K, Mayse M, Gosens R. **Antimuscarinic Bronchodilator Response Retained after Bronchoscopic Vagal Denervation in Chronic Obstructive Pulmonary Disease Patients.** *Respiration; international review of thoracic diseases* 2016; 92: 58-60.
17. Kistemaker LE, Slebos DJ, Meurs H, Kerstjens HA, Gosens R. **Anti-inflammatory effects of targeted lung denervation in patients with COPD.** *The European respiratory journal* 2015; 46: 1489-1492.
18. Slebos DJ, Klooster K, Koegelenberg CF, Theron J, Styen D, Valipour A, Mayse M, Bolliger CT. **Targeted lung denervation for moderate to severe COPD: a pilot study.** *Thorax* 2015; 70: 411-419.

November 2025



6500 Wedgwood Road North | Suite 100 | Minneapolis, MN 55311
Phone: 763-450-2800 | Fax: 763-450-2801 | nuvaira.com